BiotechTube

QR-421a

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Retinitis Pigmentosa

Conditions

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders

Trial Timeline

Mar 6, 2019 → Oct 14, 2021

NCT ID
NCT03780257

About QR-421a

QR-421a is a phase 1/2 stage product being developed by ProQR for Retinitis Pigmentosa. The current trial status is completed. This product is registered under clinical trial identifier NCT03780257. Target conditions include Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03780257Phase 1/2Completed

Competing Products

20 competing products in Retinitis Pigmentosa

See all competitors
ProductCompanyStageHype Score
DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3Sumitomo PharmaPhase 1/2
41
AGN-151597AbbViePhase 1/2
41
CPK850NovartisPhase 1/2
41
Valganciclovir + GanciclovirRochePhase 3
77
ValganciclovirRochePre-clinical
23
Foscarnet sodium + GanciclovirRochePhase 1
33
GanciclovirRochePhase 1
33
GanciclovirRochePre-clinical
23
GanciclovirRochePhase 2
52
GanciclovirRochePre-clinical
23
GanciclovirRochePre-clinical
23
Zidovudine + Sargramostim + GanciclovirRochePre-clinical
23
Zidovudine + GanciclovirRochePre-clinical
23
GanciclovirRochePre-clinical
23
Interferon beta-1b + GanciclovirRochePre-clinical
23
GanciclovirRochePre-clinical
23
GanciclovirRochePre-clinical
23
GanciclovirRochePhase 3
77
ValganciclovirRochePhase 3
77
Cidofovir + ProbenecidGilead SciencesPre-clinical
22

Other Products from ProQR

sepofarsenPhase 2/3
57
sepofarsenPhase 2/3
57
QR-1123Phase 1/2
33
QR-010 + PlaceboPhase 1/2
33
QR-504aPhase 1
25